{"filing":{"accession_number":"0001104659-26-095422","cik":"0001612940","ticker":"PRQR","company_name":"ProQR Therapeutics N.V.","form":"6-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"tm2622847d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612940/000110465926095422/tm2622847d1_6k.htm"},"events":[{"id":27447,"run_id":25022,"accession_number":"0001104659-26-095422","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a press release announcing ProQR's second quarter 2026 operating and financial results, including Q2 net loss of €8.7 million, cash position of €117.1 million, and key clinical milestones (positive AX-0810 Phase 1 target engagement data establishing first clinical validation of the Axiomer platform). The document contains unaudited interim condensed consolidated financial statements (balance sheet, P\u0026L, changes in equity) and is clearly a results announcement for the period ended June 30, 2026, making it an earnings_release rather than a periodic_quarterly report.","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-08-13","form":"6-K","submitted_at":null,"items":[{"id":28998,"accession_number":"0001104659-26-095422","item_number":"EX-99.1","item_title":"tm2622847d1_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing ProQR's second quarter 2026 operating and financial results, including Q2 net loss of €8.7 million, cash position of €117.1 million, and key clinical milestones (positive AX-0810 Phase 1 target engagement data establishing first clinical validation of the Axiomer platform). The document contains unaudited interim condensed consolidated financial statements (balance sheet, P\u0026L, changes in equity) and is clearly a results announcement for the period ended June 30, 2026, making it an earnings_release rather than a periodic_quarterly report.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:02:00.877748+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28998,"accession_number":"0001104659-26-095422","item_number":"EX-99.1","item_title":"tm2622847d1_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing ProQR's second quarter 2026 operating and financial results, including Q2 net loss of €8.7 million, cash position of €117.1 million, and key clinical milestones (positive AX-0810 Phase 1 target engagement data establishing first clinical validation of the Axiomer platform). The document contains unaudited interim condensed consolidated financial statements (balance sheet, P\u0026L, changes in equity) and is clearly a results announcement for the period ended June 30, 2026, making it an earnings_release rather than a periodic_quarterly report.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:02:00.877748+00:00","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-08-13"}]}